Depression
Conditions
Keywords
stroke, depression, cytokines, serotonin, citalopram
Brief summary
Depression is a common and often serious problem occurring in stroke patients. Inflammatory hormones, known as cytokines, are stimulated by an activated immune system and sometimes become active following a stroke. They may be responsible for altering levels of key neurotransmitters and their metabolites in the blood and brain of stroke patients. The investigators' objective is to examine whether increased cytokine activity following a stroke may be the cause of an increased presence or severity of depression or cognitive impairment among stroke patients, as a result of tryptophan depletion and/or kynurenine activation. They are recruiting patients within one month of their strokes and measuring levels of key markers in their blood. Patients are assessed for the presence of depressive and/or cognitive symptoms and treated with an antidepressant if needed. The investigators expect to show that cytokine activation is related to depression and/or cognitive impairment among stroke patients.
Interventions
DRUGCitalopram
Patients who are found to have major depression will be referred to a psychologist
Sponsors
Sunnybrook Health Sciences Centre
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Gender: male or female * Language: speaks and understands English * Clinical diagnosis of stroke according to World Health Organization MONICA Project and recent (\< 3 months) cerebral infarctions * Written, informed consent * Depressed group only: diagnosis of a major depressive episode according to the depression module of the Structured Clinical Interview for the DSM-IV (SCID-IV)
Exclusion criteria
* Subarachnoid hemorrhage * Intracranial hemorrhage * Significant acute medical illness including: drug overdose, severely disturbed liver, kidney or lung function, anemia, hypothyroidism, or uncontrolled diabetes * Significant acute neurologic illness including: impaired consciousness, Parkinson's disease, Huntington's chorea, progressive supranuclear paralysis, brain tumor, subdural hematoma, multiple sclerosis, hydrocephalus, Binswanger's disease, or severe aphasia * Presence of a premorbid Axis I psychiatric diagnosis (eg. schizophrenia, bipolar disorder) * Depressed group only: contraindications to receiving treatment with citalopram (including previous nonresponse) or serious risk of suicide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Centre for Epidemiological Studies-Depression Scale (CES-D) | Baseline, 6 weeks, 12 weeks |
| Mini Mental State Examination (MMSE) | Baseline, 6 weeks, 12 weeks |
| NINCDS-CSN Vascular Cognitive Impairment Battery | Baseline, 6 weeks, 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Modified Rankin Scale (mRS) | Baseline, 6 weeks, 12 weeks |
| NIH Stroke Scale | Baseline, 6 weeks, 12 weeks |
Countries
Canada
Outcome results
None listed